Value of IL-27, IL-29 and miRNA-497 in radioactive particles combined targeted therapy in patients with HER-2 positive gastric cancer
10.3969/j.issn.1671-8348.2017.30.009
- VernacularTitle:IL-27、IL-29及miRNA-497在HER-2阳性胃癌患者放射性粒子联合靶向治疗中的价值
- Author:
Tao XIANG
1
;
Hui LEI
;
Qiqiong TAN
;
Yanyin WU
;
Fengqing MO
;
Bo HU
;
Tiantian XIANG
Author Information
1. 广东省吴川市人民医院内8科
- Keywords:
stomach neoplasms;
ascites;
interleukin-27;
interleukin-29;
miRNA-497;
HER-2;
radioactive particles;
targeted therapy
- From:
Chongqing Medicine
2017;46(30):4204-4206
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of IL-27,IL-29 and miRNA-497 in HER-2 positive radioactive particles combined targeted therapy. Methods Sixty-one elderly inpatients with HER-2 positive gastric cancer ascites in the Gaoming District People's Hospital, Wuchuan Municipal People's Hospital and Zhejiang Provincial Tumor Hospital were divided into the two groups. The treatment group(n= 31) was treated by the radioactive particles+ targeted drug Trastuzumab(initial dose 8 mg/kg, maintenance dose 66 mg/kg, once per 3 weeks) for 6 weeks; the control group(30 cases) was treated by targeted drug Trastuzumab (initial dose 8 mg/kg,maintenance dose 6 mg/kg, once per 3 weeks) for 6 weeks. The levels of ascites IL-27,IL-29 and miRNA-497 in the radioactive partcles combined targeted therapy group and control group were detected. Results The levels of ascites IL-27, IL-29 and miRNA-497 after treatment in the treatment group were significantly decreased compared with those before treatment and in the control group,the effective remission rate in the treatment group was 74. 19%, which was higher than 36.67% in the control group, the average median survival time in the treatment group was 155 d, which washigher than 72 d in the control group, the difference was statistically significant. Conclusion IL-27 ,IL-29 and miRNA-497 has the significance of curative effect evaluation and prognosis judgment in the radioactive particles combined targeted therapy for the patients with HER 2 positive gastric cance.
